Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan

NOBUYOSHI FUKUMITSU, HITOSHI ISHIKAWA, TAKESHI ARIMURA, HITOSHI WADA, TOMOAKI OKIMOTO, YOSHITAKA SATO, HIROMITSU IWATA, SHOSEI SHIMIZU and HIDEYUKI SAKURAI
In Vivo September 2020, 34 (5) 2883-2889; DOI: https://doi.org/10.21873/invivo.12116
NOBUYOSHI FUKUMITSU
1Department of Radiation Oncology, Kobe Proton Center, Hyogo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI ISHIKAWA
2Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan
3National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ishikawa.hitoshi@qst.go.jp
TAKESHI ARIMURA
4Medipolis Proton Therapy and Research Center, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI WADA
5Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Fukushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOAKI OKIMOTO
6Department of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHITAKA SATO
7Proton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROMITSU IWATA
8Departments of Radiation Oncology, Nagoya City West Medical Center, Aichi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOSEI SHIMIZU
2Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEYUKI SAKURAI
2Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. Patients and Methods: The survival, local control, and toxicities in 22 RCC patients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. Results: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95% and 100%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood urea nitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1±11.2 ml/min/1.73 m2. Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients.

  • Renal cell carcinoma
  • proton beam therapy
  • local control
  • toxicity
  • radiotherapy
  • Received June 2, 2020.
  • Revision received June 27, 2020.
  • Accepted June 29, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

In Vivo
Vol. 34, Issue 5
September-October 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan
NOBUYOSHI FUKUMITSU, HITOSHI ISHIKAWA, TAKESHI ARIMURA, HITOSHI WADA, TOMOAKI OKIMOTO, YOSHITAKA SATO, HIROMITSU IWATA, SHOSEI SHIMIZU, HIDEYUKI SAKURAI
In Vivo Sep 2020, 34 (5) 2883-2889; DOI: 10.21873/invivo.12116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan
NOBUYOSHI FUKUMITSU, HITOSHI ISHIKAWA, TAKESHI ARIMURA, HITOSHI WADA, TOMOAKI OKIMOTO, YOSHITAKA SATO, HIROMITSU IWATA, SHOSEI SHIMIZU, HIDEYUKI SAKURAI
In Vivo Sep 2020, 34 (5) 2883-2889; DOI: 10.21873/invivo.12116
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Factors for Discontinuation of Naldemedine Therapy in a Palliative Ward
  • Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
  • Microstructural, Electrochemical, and Mechanical Assessment of Additive Manufactured Titanium Grade 23 for Dental Implants Application
Show more Clinical Studies

Similar Articles

Keywords

  • renal cell carcinoma
  • proton beam therapy
  • local control
  • toxicity
  • radiotherapy
In Vivo

© 2025 In Vivo

Powered by HighWire